Reviewing the state of the art of probiotics as clinical modalities for brain-gut-microbiota axis associated disorders.

ABSTRACT: The rise in prevalence of mental and neurological disorders is causing a high burden on society, however adequate interventions are not always available. The brain-gut-microbiota axis (BGMA) may provide a new angle for the development of clinical modalities. Due to the intricate bi-directional signaling between the brain and the gut, it may be helpful to look into interventions that target the gut, such as probiotics. Therefore, this review aimed to investigate the state of the art of probiotics and their potential as clinical modalities for BGMA-associated indications by gaining insight into patents and clinical trials that have been applied for and executed since 1999. A total of 565 patents and 390 clinical trials were found, focusing on probiotic applications for 83 indications. Since

SUBMITTER: Wiegers C 

PROVIDER: S-EPMC9732675 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature